Week In Review: Shanghai Pharmaceutical Co., Ltd. Considers $4 Billion Bid For Germany's Stada

Shanghai Pharma may bid $4 billion to acquire Stada, a German generic drugmaker currently in a bidding war; Athenex, a US-China biopharma, filed to raise $100 million in a US IPO on the NASDAQ exchange; Beijing Sinobioway will pay $50 million to add five new CAB antibody targets to its collaboration with BioAtla, a San Diego-Beijing biotech; Aslan Pharma of Singapore completed the competitive auction part of its $30 million Taiwan IPO; 3SBio of Shenyang entered a strategic cooperation agreement to market Lilly's insulin product, Humulin®, in China; Beijing's CANbridge Life Sciences partnered with Amoy Diagnostics of Xiamen to develop a companion diagnostic assay for CANbridge’s brain cancer treatment; Germany's Boehringer Ingelheim officially opened its $77 million China biologic drug contract manufacturing facility in Shanghai; and the CFDA is circulating draft proposals for broad-based reforms that will speed CFDA response times and increase IP protection.